Failing early in biotherapeutics development saves time and cost by enabling early candidate screening for binding specificity, safety, stability, and degradation. Traditional label-free techniques are often costly, complex, and slow, with high sample requirements and media compatibility issues.
Alto streamlines antibody development by simplifying epitope binning, Fc receptor binding, affinity maturation, and charge variant characterization. Its rapid assay optimization and high-quality data in complex media ensure precise binding kinetics analysis and reliable differentiation between candidates.
Failing early in biotherapeutics development saves time and cost by enabling early candidate screening for binding specificity, safety, stability, and degradation. Traditional label-free techniques are often costly, complex, and slow, with high sample requirements and media compatibility issues.
Alto streamlines antibody development by simplifying epitope binning, Fc receptor binding, affinity maturation, and charge variant characterization. Its rapid assay optimization and high-quality data in complex media ensure precise binding kinetics analysis and reliable differentiation between candidates.
Alto’s digital SPR rapidly differentiates overlapping epitopes with high resolution using minimal sample, identifying unique binding sites for up to 16 drug candidates.
Analyze multiple candidates in parallel, enhancing efficiency over traditional SPR without complex operational demands.
Obtain precise on/off rates and affinity constants for antibody-antigen and Fc receptor interactions, delivering results comparable to traditional SPR and BLI.
Extend Alto’s capabilities into regulated environments, seamlessly transitioning assays from development to quality control in manufacturing.
Assess biosimilarity, stability, and charge variant performance across acidic/basic variants, biosimilars, and stressed samples.
Alto enables up to 16×16 pairwise epitope binning, capturing antigens with up to 16 unique surface-coupled antibodies in a classical sandwich format. Using DMF technology, Alto automates and optimizes binning assays with just 1 µg of antigen and 100 ng of antibody, reducing complexity, cost, and effort with one-click data analysis.
Alto enables up to 16×16 pairwise epitope binning, capturing antigens with up to 16 unique surface-coupled antibodies in a classical sandwich format. Using DMF technology, Alto automates and optimizes binning assays with just 1 µg of antigen and 100 ng of antibody, reducing complexity, cost, and effort with one-click data analysis.
Heat map of 16×16 epitope binning of anti-HA antibodies against the HA antigen, with blue indicating ‘bind’.
| Sino Cat # | KD(M) | Sino Cat # | KD(M) | Sino Cat # | KD(M) |
|---|---|---|---|---|---|
|
RM08 |
5.53E-12 |
RM09 |
1.33E-11 |
RM02 |
1.37E-10 |
|
MM14 |
7.18E-12 |
MM04 |
1.35E-11 |
MM08 |
1.73E-09 |
|
MM01 |
1.10E-11 |
MM06 |
2.16E-11 |
RM06 |
3.11E-09 |
|
MM11 |
1.13E-11 |
RM07 |
6.02E-11 |
MM05 |
3.15E-09 |
|
MM03 |
1.22E-11 |
MM10 |
1.10E-10 |
RM01 |
6.54E-09 |
Biotherapeutic charge heterogeneity analysis and charge variant fraction collection workflow with the MauriceFlex System, followed by binding analysis on the Alto System.
Alto’s 16 independent channels enable simultaneous multi-target analysis across various assay formats with full automation, minimizing hands-on time. Here, we demonstrate Alto’s efficiency in measuring FcγR-IgG1 binding kinetics. Its streamlined workflow reduces batch preparation efforts and accelerates biologic discovery.
Representative kinetic fits for IgG1 binding to (A) HIS-FcyRI, (B) HIS-FcyRIIA and (C) HIS-FcyRIIIA captured on Nicoya’s anti-HIS sensors using multi-cycle kinetics (MCK). The Tocilizumab analyte concentrations are shown in the figure legends. The black curve represents the Langmuir 1:1 binding fit.
Designing label-free biosensor assays for Fc receptor binding analysis: Meeting research challenges.
